Greenland Mines (formerly Klotho Neurosciences) is a pre-revenue development-stage company with three platforms: gene therapy for neurodegenerative diseases, oncology biosimilars and generics, and a newly acquired critical and precious minerals mining business. The core scientific focus is gene therapy using a secreted protein called α-Klotho (s-KL), based on the premise that Klotho levels naturally decline with age and that restoring s-KL in the brain may protect neurons and slow cognitive and motor decline. The two lead gene therapy candidates are KLTO-101, targeting Alzheimer's disease, and KLTO-202, targeting ALS — both are in preclinical development with no IND applications filed. R&D is conducted primarily through an academic partnership with the Universitat Autònoma de Barcelona. The company also holds licenses from Reliance Life Sciences to develop biosimilars of rituximab, bevacizumab, trastuzumab, and cetuximab in North America, Europe, and Israel, and owns market authorizations for five approved generic cancer drugs in Germany. In March 2026, the company acquired Greenland Mines Corp., adding critical and precious minerals development to its portfolio. The company has only two full-time U.S. employees and no product revenue, and is funded through capital raises. Near-term priorities include completing animal toxicology work for KLTO-202 and filing an IND for a Phase 1 ALS study, while pursuing a partner for KLTO-101.